Kymab is set to receive a $30 million (€26 million) investment from LifeArc in return for access to antibody discovery technologies. In return, Kymab is granting LifeArc access to its IntelliSelect platforms, a suite of technologies made up of several genetically engineered mouse strains. Source: Fierce Biotech 24/6/2019